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BACKGROUND: Chronic pain is a frequent cause of suffering and dis-
ability that negatively affects patients’ quality of life. There is growing
evidence that disparities in the treatment of pain occur because of dif-
ferences in race.
OBJECTIVE: To determine whether race plays a role in treatment de-
cisions involving patients with chronic nonmalignant pain in a primary
care population.
DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional survey
was administered to patients with chronic nonmalignant pain and
their treating physicians at 12 academic medical centers. We enrolled
463 patients with nonmalignant pain persisting for more than 3
consecutive months and the primary care physicians participating in
their care.
RESULTS: Analysis of the 397 black and white patients showed that
blacks had significantly higher pain scores (6.7 on a scale of 0 to 10,
95% confidence interval (CI) 6.4 to 7.0) compared with whites (5.6, 95%
CI 5.3 to 5.9); however, white patients were more likely to be taking
opioid analgesics compared with blacks (45.7% vs 32.2%, Po.006).
Even after controlling for potentially confounding variables, white pa-
tients were significantly more likely (odds ratio (OR) 2.67, 95% CI 1.71
to 4.15) to be taking opioid analgesics than black patients. There were
no differences by race in the use of other treatment modalities such as
physical therapy and nonsteroidal anti-inflammatories or in the use of
specialty referral.
CONCLUSION: Equal treatment by race occurs in nonopioid-related
therapies, but white patients are more likely than black patients to be
treated with opioids. Further studies are needed to better explain this
racial difference and define its effect on patient outcomes.
KEY WORDS: pain therapy; primary care; racial disparities; decision
making; minority groups; delivery of health care.
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C hronic pain is a major health issue worldwide and has aprofound effect on quality of life. Data from the World
Health Organization estimate that 22% of primary care pa-
tients report persistent pain.1 In the United States alone, sev-
eral studies indicate that millions of adults suffer a heavy
burden from this symptom.2,3 Because of lost work and pro-
ductivity, estimates for the economic loss associated with
chronic pain reach as high as $61 billion per year.4
Although the treatment of pain and suffering should be a
priority for all physicians, and the capacity to treat pain has
never been greater, it is well established that pain is not opti-
mally treated.5–7 This fact, coupled with the 2002 Institute of
Medicine report concerning unequal treatment in racial and
ethnic minorities, raises the possibility that the treatment of
chronic pain in primary care settings might differ, especially
for blacks.8 There is now growing evidence to suggest that dis-
parities in the treatment of pain in racial and ethnic minorities
also exist.9–15 However, most of these studies have been con-
ducted in an acute setting or are cancer related.
The 4P Study (Patient Physician Perception of Pain) was
designed to better understand chronic nonmalignant pain pa-
tients and their treatment in the primary care setting. The
specific objective for this part of the study was to determine




The 4P Study was conducted from July 2002 to March 2003 at
12 academic medical centers in the United States. Patients
were recruited from the primary care practices of each center,
including both resident and attending physician practices. The
Institutional Review Boards at all centers approved the study
protocol.
Patient Selection and Recruitment
Patients were eligible for enrollment if they were at least 18
years of age and reported a history of pain for at least 3 con-
secutive months. We excluded pregnant females, patients not
fluent in English or Spanish, incarcerated individuals, pa-
tients being treated for active cancer, and patients with docu-
mented cognitive impairment such as dementia.
During the course of routine clinic check-in procedures,
the research assistant, triage nurse, or treating physician
identified eligible patients. The research assistant then evalu-
ated patients for exclusion criteria, obtained informed
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consent, and administered the 82-item survey verbally in a
secluded location.
Survey Instrument
The initial patient survey included questions about demo-
graphic information, general health and pain perceptions,
treatment choices, and attitudes toward provision of medical
care. The survey also included the numeric rating scale (NRS-
11),16 a standardized pain assessment tool used to measure
pain intensity, where pain scores range from 0 (no pain) to 10
(unbearable pain). Patients were shown the NRS-11 and re-
sponses to the question ‘‘How severe is your pain today?’’ were
recorded.
Pain Medication Use
Patients were specifically asked the types of medicines that
they were currently taking for their pain and whether by pre-
scription, over the counter, or by illicit means. The research
assistants were instructed to ask patients, ‘‘What medicines
are you taking now for your pain?’’ The research assistant pro-
vided each patient with a complete list of examples from each
class: (1) nonsteroidal anti-inflammatories (NSAIDS) such as
Motrin, Advil, Celebrex, Goody’s Powders, and Aspirin, (2)
Acetaminophen or Tylenol, (3) weak opioids such as Darvocet,
Tylenol III, and Vicodin, (4) strong opioids such as Demerol,
Morphine, Percocet, Oxycodone, and Dilaudid, (5) long-acting
opioids such as Oxycontin, MS Contin, and Duragesic patch-
es, (6) adjuvant medications such as Elavil or Gabapentin, (7)
the ‘‘atypical’’ analgesic Ultram, and (8) substance-abuse
‘‘medications’’ such as alcohol, marijuana, heroin, and co-
caine. Patients could choose multiple classes, and for purpos-
es of analysis we considered patients to be taking opioid
medications if they were taking Schedule II, III, and IV drugs
as defined by the Drug Enforcement Agency (classes 3, 4, and
5 above).
Race
Patients were asked to self-report their racial status from a list
of 16 groups. The 3 major groups were classified as (1) white,
(2) black, African American or Negro, or (3) Spanish, Hispanic,
or Latino. Because of insufficient numbers, Hispanic patients
and other races such as Indian, Chinese, Filipino, Japanese,
or Korean were excluded from this analysis.
Treatment Choices
As a measure of other treatment choices, patients were asked
whether they had previously seen different types of specialists
or nonprimary care providers for their pain such as a rheum-
atologist, orthopedist, pain specialist, chiropractor, podiatrist,
reflexologist, acupuncturist, or herbalist. Patients were also
asked whether they had undergone physical therapy as a mo-
dality to improve their pain.
Other Covariates
Other medical conditions reported by patients included any of
15 common chronic diseases including diabetes, hyperten-
sion, arthritis, stroke, or emphysema. The type of health in-
surance, the current number of hours per week the patient
worked, whether the patient received a disability check, an-
nual income, and the years of schooling completed were also
documented as elements of socioeconomic status. The re-
search assistant also documented whether a resident or at-
tending physician was the primary care provider for the
patient on the study day.
Statistical Analyses
Statistical analyses were performed using Stata 7.0 (Stata
Corp., College Station, Tex). Descriptive statistics for the de-
mographic variables, the use of opioids, the different treatment
modalities, and other covariates as described above were per-
formed. Race was analyzed as black versus white, physician
level as resident versus attending, and the presence of comor-
bidities, insurance status, and disability check status were di-
chotomized as yes or no. Age, duration of pain, educational
level, and number of current hours worked were analyzed as
continuous variables.
The primary outcome variable was any opioid use by the
patient. We also performed additional analysis considering the
3 classes of opioids (weak, strong, and long acting). In these
analyses, persons reporting the use of more than one class of
opioid were classified hierarchically as follows: long acting,
strong, weak, and none. Thus, a person reporting both long-
acting and weak opioid use would be classified in the
long-acting group. Four additional outcome variables includ-
ed patients’ use of other treatment modalities, including (1)
NSAIDS, (2) physical therapy, (3) pain specialists, and (4) other
specialists. The use of orthopedists, rheumatologists, chiropr-
actors, podiatrists, reflexologists, acupuncturists, and herbal-
ists were all grouped into the category of other specialists
because of the low overall percentage of referrals for the last
five groups.
We performed bivariate analyses of race versus other de-
mographic data, level and duration of pain, comorbidities, and
other socioeconomic-related covariates. We then compared
race with the prevalence of opioid use and the other 4 treat-
ment choices. We applied 2-sample t tests, w2, and Wilcoxon
rank sum tests as appropriate. Variables that were significant
(Po.05) in bivariate analysis and variables of particular inter-
est that might predict opioid use or treatment decisions were
included in the final regression models. We used multiple lo-
gistic regression to assess the relationship between race and
each outcome while adjusting for potential confounding by
age, sex, pain severity and duration, comorbidities, disability
status, and elements of socioeconomic status. Additionally, in
order to examine any effect of physician experience on race
and opioid utilization, we ran separate models stratified by
physician level of training. We used 2-sided P values of less
than .05 to indicate statistical significance. In the logistic re-
gression analysis, robust variance estimates were used to ac-
count for clustering by site.
RESULTS
We enrolled 463 patients of the 601 patients ap-
proached (77%). Twenty-three patients were excluded because
of pregnancy, dementia, and incarceration, and 115 patients
declined to participate. Fifty-eight patients were classified as
Hispanic or ‘‘Other’’ race, and no race data were available on
eight patients, leaving a total of 397 patients available for anal-
ysis. Demographic data are reported in Table 1.
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Of the 397 patients, 219 (55%) were white and 178 (45%)
were black. Overall, more women participated than men, and
this gender predominance was more significantly reflected
among black participants. Significantly more blacks than
whites were uninsured (34% vs 16%, Po.001), but there were
no other socioeconomic differences such as disability status or
income.
Depression was reported more commonly in whites than
blacks (45.6% vs 32.0%, P=.006), but there were no signifi-
cant differences in other reported comorbidities or body mass
index. There were no significant differences in the proportion
of patients seen by resident versus attending physicians, and
75% of patients stated that they saw their regular primary care
provider often or always. Forty percent of all patients reported
2 or more body sites affected by chronic pain, with the lower
back being the most commonly mentioned site.
The majority of patients (81%) experienced pain for at
least a year, but whites reported suffering longer (median
months 60 vs 39, P=.002). Blacks had significantly higher
pain scores (mean 6.7, 95% confidence interval (CI) 6.4 to 7.0)
compared with whites (mean 5.6, 95% CI 5.3 to 5.9). There
were no significant racial differences in the percentage of
patients currently not working and currently receiving a disa-
bility check.
Treatment Choices
Of the different treatment choices, the most common was us-
age of NSAID medications followed by treatment by a physical
therapist. About 40% of patients reported ongoing use of op-
ioid analgesics. Among those referred for specialty care, 34% of
patients had seen a pain specialist, and the most common re-
ferrals in the ‘‘other specialists’’ group were to orthopedic phy-
sicians (21%) and rheumatologists (16%).
Table 2 depicts significant bivariate differences between
blacks and whites regarding the different treatment modali-
ties. Whites were more likely to be treated with opioids than
blacks (45.7% vs 32.2%, P=.006) and more likely to receive
physical therapy (46.8% vs 35.1%, P=.02). There were no sig-
nificant racial differences in the use of NSAIDS, pain special-
ists, or other specialty providers.
Table 3 reports all analgesic use according to race. The
breakdown of opioid usage revealed that whites were signifi-
cantly more likely to receive stronger (Po.03) and longer-act-
ing (Po.001) opioids. There were no significant differences in
the use of acetaminophen, adjuvant medications, Ultram, or
illicit substances, but only 7 patients (1.8%) admitted to using
substances of abuse to treat their pain.
In bivariate analysis, opioid use also correlated with a
younger age (P=.04), higher pain score (Po.001), and having
seen an attending physician (49.5% vs 36.1%, Po.02). Gender,
insurance status, educational level, duration of pain, presence
of depression, income, current number of hours worked, and
receipt of a disability check were not associated with opioid
use. The use of physical therapy was related to higher pain
scores (Po.02), having health insurance (Po.03), and a higher
educational level (Po.02), but not with other demographic
variables, physician level, or use of opioid medications.
Regression Analyses
We performed a logistic regression analysis on the 2 outcomes
(use of opioids and use of physical therapy) with racial differ-
ences in bivariate analysis to assess whether race remained a
significant variable after controlling for other factors. As
shown in Table 4, whites were more than twice as likely (odds
ratio (OR) 2.67, 95% CI 1.71 to 4.15) to be on opioids than
blacks. In models exploring opioid use by category, we found







Age, mean years (SD) 53.4 (  11.9) 53.4 (  13.3) .96
Married 91 (41.6%) 42 (23.6%) o.001
Sex
Male (n=123) 84 (38.4%) 39 (21.9%)
Female (n=274) 135 (61.6%) 139 (78.1%) o.001
Educational level,
mean years (  SD)
12.3 (  3.4) 11.6 (  2.6) .03





BMI, mean (SD)w 32.6 (  7.9) 32.3 (  9.2) .69
Top five major comorbiditiesz Patients having disorder (%)
Arthritis (n=273) 70.3 66.9 .46
Hypertension (n=208) 48.9 56.7 .12
Depression (n=157) 45.6 32.0 .006
Emphysema (n=101) 28.8 21.4 .09






of pain in months (IQR)
60 (26 to 120) 39 (13 to 96) .002
Mean pain score
(0 to 10)







Sixty-six out of 463 (14%) patients identifying themselves as Cuban
(14), Mexican (6), Other Hispanic (25), American Indian (6), Multi-Race
individuals (5), Other (2), and No Race (8) were excluded from the anal-
ysis between White and Black patients.
wBody mass index (BMI) calculated from patient’s self-estimated height
and weight.
zSelf-reported comorbidities included diabetes, hypertension, CAD, de-
pression, emphysema, heart failure, thyroid disease, HIV/AIDS, liver
disease, arthritis, kidney disease, stomach ulcers, paralysis from
stroke, poor circulation.
IQR, interquartile range; CAD, coronary artery disease.









Use of NSAIDS 46.6 50.3 .46 191 (48.2)
Use of physical
therapy
46.8 35.1 .02 162 (41.5)
Use of opioids 45.7 32.2 .006 157 (39.6)
Use of pain
specialist
37.6 30.8 .16 135 (34.6)
Use of other
specialistsw
41.5 37.5 .42 156 (39.7)
Po.05.
wOther specialists include orthopedist, rheumatologist, chiropractor, acu-
puncturist, podiatrist, reflexologist, and herbalist.
NSAIDS, non-steroidal anti-inflammatories.
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that racial differences were more pronounced when consider-
ing stronger opioids (OR 3.62 in favor of whites, 95% CI 1.75
to 7.46) and longer-acting opioids (OR 3.08, 95% CI 1.35 to
7.06). Opioid use was also associated with higher pain severity
(OR 1.25, 95% CI 1.09 to 1.44) and duration of pain (OR 0.997,
95% CI 0.995 to 0.999), but not with any other variables stud-
ied. When stratified by physician level, the relationship be-
tween race and opioid use persisted (resident OR 2.81, 95% CI
1.27 to 6.26, and attending OR 2.59, 95% CI 1.12 to 5.97), and
an interaction term between race and physician level in the
regression model confirmed that the effect of race did not differ
across type of physician. To test for potential site biases, a test
of homogeneity was performed and did not demonstrate a site
effect.
The difference in utilization of physical therapy by whites
and blacks was not significantly different (OR 1.46, 95% CI
0.89 to 2.37) after controlling for other demographics. Instead,
we found simply that patients reporting higher pain levels used
physical therapy more frequently (OR 1.15, 95% CI 1.01 to
1.32). Physician level did not affect the relationship between
physical therapy and race in this model.
DISCUSSION
This study suggests that patient race plays a significant role in
the management of chronic nonmalignant pain in the primary
care setting. Our results show that whites were significantly
more likely to be using opioid analgesics, particularly stronger
and longer-acting opioids, in the treatment of chronic pain as
compared with blacks. This disparity occurred in the setting of
blacks having significantly higher pain scores compared with
whites. Interestingly, race did not play a role in pain manage-
ment with nonopioid-related therapies. Although disparities in
opioid prescribing have been described in the acute and hos-
pital setting,9–11 to our knowledge this is the first study that
demonstrates this disparity in an ambulatory primary care
setting.
Why, then, does the disparity between blacks and whites
exist for opioid usage, but not for the nonopioid therapies? The
existence of disparities in the use of opioids has been theorized
to exist for such reasons as inadequate physician training,17,18
lack of availability of opioids at pharmacies,19 low pain relief
goals among physicians,6,20 discordance or disagreement in
pain levels between patients and physicians,21–23 and opioi-
phobia (the fear of prescribing opioids) among physi-
cians.18,24–26
Based on our study, we do not believe that the racial dis-
parity for opioid usage is related to problems of access or
health care systems. Even though blacks were more likely to
be uninsured, the presence of insurance itself had no bearing
on the different types of treatment available. In addition,
whites and blacks in our study were similar with regard to
other socioeconomic elements. If there were differences related
to access or referrals, we would expect a difference in the usage
of the other 4 treatment strategies (which are also more ex-
pensive) as well, but this was not the case.
We also believe that the racial disparity is not because of
patient preferences or behaviors. There is evidence that sug-
gests that chronic pain affecting blacks is experienced differ-
ently when compared with the experiences of whites, and that
blacks have greater pain severity and disability with poorer
quality of life.27–32 We would expect, therefore, that blacks uti-
lize more treatment modalities than whites; yet, this was not
the case. Although we cannot explain the directionality of the
relationship between pain scores and opioid use (did opioid
use lead to lower pain scores, or are there lower pain scores
because of opioid use?), the relationship observed among
blacks is problematic: significantly higher pain scores among
blacks should result in more opioid usage, not less.
If there are no obvious access problems or patient-related
factors, we are left to consider whether physicians are simply
undertreating minorities with chronic pain. Undertreatment
of pain among minorities by physicians has been previously
documented in acute settings9,11,15 and in studies examining
the treatment of cancer-related pain.10,12 One possible expla-
nation for this racial disparity could be physicians’ level of
training. However, when we analyzed opioid use and race and
Table 3. Breakdown of Medication Usage by Race
Type of medication White patients (n=219) Black patients (n=178) P-value Total N (%)
NSAIDS 102/219 (46.6%) 89/177 (50.3%) .46 191/396 (48.2)
Acetaminophen 61/219 (27.9%) 57/177 (32.2%) .35 118/396 (29.8)
Opioids (Total) 100/219 (45.7%) 57/177 (32.2%) .006 157/396 (39.6)
Weak 40/159 (25.2%) 35/155 (22.6%) .59 75/314 (23.9)
Strong 28/147 (19.1%) 13/133 (9.8%) .03 41/280 (14.6)
Long acting 32/151 (14.6%) 9/129 (7.0%) .001 41/280 (14.6)
Adjuvant 22/219 (10.1%) 16/177 (9.0%) .74 38/396 (9.6)
Ultram 18/219 (8.2%) 9/177 (5.1%) .22 27/396 (6.8)
Illicits 4/219 (1.8%) 3/177 (1.7%) .92 7/396 (1.8)
One African-American patient did not answer the questions on medication usage.
NSAIDS, non-steroidal anti-inflammatories.
Table 4. Logistic Regression Identifying Significant Correlations
with Opioid Use
Variables Odds ratio 95% CI P-value
Race, white 2.67 1.71 to 4.15 o.001
Higher degree of pain 1.25 1.09 to 1.44 .002
Older age 0.99 0.98 to 1.00 .07
Gender, male 1.32 0.55 to 3.17 .53
Duration of pain (mo) 0.997 0.995 to 0.999 .02
Insurance status: yes 1.14 0.62 to 2.12 .67
Educational level 1.06 0.99 to 1.13 .11
Comorbidity (depression) 0.92 0.63 to 1.35 .67
Current work hours 0.99 0.97 to 1.01 .33
Disability check 1.35 0.75 to 2.43 .31
Use of physical therapy 1.00 0.54 to 1.85 .99
Po.05.
CI, confidence interval.
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whether a physician was a resident or attending, we found that
the disparity in opioid use between blacks and whites was not
modified by physicians’ level of training. Our study methodol-
ogy does not allow us to determine the reason why physicians
may underuse opioid medications, particularly stronger and
more potent opioids, in blacks. The more pronounced racial
differences for strong and long-acting opioids suggest that sys-
tematic mistrust, bias, or stereotyping phenomena could be in
play. If physicians are not writing prescriptions, is it because
of cultural communication barriers or mistrust that may cause
one to discount a patient’s pain report? A study by van Ryn
and Burke33 does suggest that physicians hold negative
views of blacks and believe that they are less compliant. Al-
ternatively, if patients are not filling the prescription, is the
reason financial or a fear of addiction that stems from mis-
communication during the clinical encounter?
An alternative explanation for the racial disparity in op-
ioid use is that whites as a group, may be overtreated
rather than blacks being undertreated. The prevalence of pre-
scription abuse has risen sharply in the last 10 years and the
annual incidence of prescription abuse in whites is significant-
ly higher than blacks (6.9% vs 3.7%).34 Additionally, mental
illness is strongly associated with substance abuse, and a
significantly higher proportion of whites in our study
had a history of depression. It may be possible that the pres-
ence of depression is leading to overutilization of opioids
in whites.
The question of undertreatment of blacks with chronic
pain versus overtreatment of whites cannot be answered by
our methodology. The fact that opioids were clearly used more
frequently by whites and the findings of previous studies in the
emergency department, cancer-related, and postoperative set-
tings argue for the likelihood that blacks are undertreated. For
now, efforts to eliminate racial disparities must include patient
and physician education, as well as increased awareness of the
problem. Many articles have highlighted the need for more
pain education among physicians,17,20,24,35,36 but training in
cultural competency may also be needed.
Our study has specific limitations, including the fact that
the research subjects are a sample of convenience. Many of
these patients were poor and were treated in an academic set-
ting, so generalizability is a concern. Nonresponder bias can
also be entertained. However, the fact that we recruited pa-
tients from 12 centers from a variety of geographic locations
with only modest refusal to participate suggests that the im-
pact of these issues is minimal. Also, given the observational
nature of our study, it is impossible for us to ascertain cause
and effect. Despite these limitations, the data demonstrate
that racial disparities in chronic pain management continue
to be a significant health issue.
CONCLUSION
In a primary care setting, whites with chronic pain are more
likely to be treated with opioids than blacks. No inequality
of treatment occurred when utilizing nonopioid therapies.
Further efforts are needed to better understand why these
treatment differences exist. However, increased physician
awareness and education on these disparities would be an im-
portant initial step toward equalizing racial pain management.
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